Arvinas (ARVN) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Arvinas (ARVN) has outperformed REGENXBIO (RGNX) over the past year, losing 23.0% versus a loss of 33.8%. Over five years, RGNX leads with a -77.5% price change compared with -91.2% for ARVN. REGENXBIO is the larger company by market cap ($533.4 million vs $490.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | RGNX |
|---|---|---|
| Share price | $7.61 | $8.08 |
| Market cap | $490.68M | $533.39M |
| 1-day change | +1.26% | -0.12% |
| YTD return | -36.68% | -43.82% |
| 1-year return | -22.97% | -33.80% |
| 5-year return | -91.18% | -77.50% |
| P/E ratio (TTM) | 29.25 | — |
| EPS (TTM) | $0.26 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.51 | $16.19 |
| 52-week low | $6.97 | $5.46 |
| Distance from 52-week high | -47.59% | -50.09% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +83.17% | +191.83% |
| Average volume | 788.21K | 1.53M |
| Shares outstanding | 64.52M | 66.01M |
| Employees | 246 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARVN has outperformed RGNX by 10.8 percentage points over the past year.
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
ARVN vs RGNX FAQ
Which is bigger, Arvinas or REGENXBIO?
REGENXBIO (RGNX) is larger, with a market capitalization of $533.39M compared with $490.68M for Arvinas (ARVN).
Which stock has performed better over the past year, ARVN or RGNX?
ARVN returned -22.97% over the past 12 months, compared with -33.80% for RGNX (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and REGENXBIO in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Arvinas and Biotechnology: Biological Products (No Diagnostic Substances) for REGENXBIO.